Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316212 · ClinicalTrials.gov registry record · Phase 2
Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00316212 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 160 participants.
The verdict
NCT00316212, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this trial is to identify a dose or doses of INS50589 intravenous infusion that are well-tolerated and which reduce postoperative bleeding and blood product transfusion.
Interventions
- DRUG INS50589 Intravenous Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316212
The ClinicalTrials.gov registry entry for NCT00316212 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INS50589 Intravenous Infusion is the first listed.
NCT00316212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316212 about?
NCT00316212 is a clinical study titled "Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass". The purpose of this trial is to identify a dose or doses of INS50589 intravenous infusion that are well-tolerated and which reduce postoperative bleeding and blood product transfusion.
What is the current status of trial NCT00316212?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2006-04.
What interventions are being tested in trial NCT00316212?
The interventions under investigation include: INS50589 Intravenous Infusion (DRUG).
Who is sponsoring clinical trial NCT00316212?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.